Skip to main content
Jiangxi Synergy Pharmaceutical Co.,Ltd. logo

Jiangxi Synergy Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 300636 ISIN · CNE100002P83 LEI · 836800AMA4MDGZBPAQ18 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,207 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300636

About Jiangxi Synergy Pharmaceutical Co.,Ltd.

https://www.jxsynergy.com

Jiangxi Synergy Pharmaceutical Co.,Ltd. specializes in the research, development, production, and sale of steroid hormone active pharmaceutical ingredients (APIs) and their intermediates. The company maintains a comprehensive product portfolio that includes progesterone, medroxyprogesterone acetate, and various corticosteroid derivatives. Utilizing advanced chemical synthesis and fermentation technologies, the firm provides high-purity components for the global pharmaceutical market. Its operations are characterized by a commitment to rigorous quality management systems and compliance with international manufacturing standards. The company serves a diverse clientele of pharmaceutical formulators, focusing on delivering specialized chemical solutions for hormonal therapies and related medical applications.

Recent filings

Filing Released Lang Actions
上海市通力律师事务所关于江西同和药业股份有限公司2025年年度股东会的法律意见书
Regulatory Filings
2026-05-19 Chinese
2025年年度股东会决议公告
Regulatory Filings
2026-05-19 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 85% confidence The document is a corporate announcement of receiving a drug registration certificate from the national drug regulatory authority. It is not reporting financial results, dividends, board changes, share transactions, or other specified categories. It is a general regulatory announcement regarding product approval, which falls under the fallback category ‘Regulatory Filings’ (RNS).
2026-05-18 Chinese
招商证券股份有限公司关于江西同和药业股份有限公司2025年度持续督导跟踪报告
Regulatory Filings Classification · 82% confidence The document is a continuous supervision tracking report (“持续督导跟踪报告”) issued by the sponsor (招商证券股份有限公司) on its oversight of 江西同和药业股份有限公司 for 2025. It does not contain financial statements or performance metrics, but rather details compliance and review activities as required by the exchange/regulator. This is a regulatory compliance filing without substantive financial results or audit opinions. Therefore, it falls under the miscellaneous regulatory announcements category: Regulatory Filings (RNS).
2026-05-14 Chinese
招商证券股份有限公司关于江西同和药业股份有限公司向特定对象发行股票持续督导保荐总结报告书
Regulatory Filings Classification · 85% confidence The document is a “持续督导保荐总结报告书” (Continuous Supervision Sponsorship Summary Report) prepared by the sponsoring broker (招商证券) under China’s securities regulations. It is a compliance report on the sponsor’s ongoing supervision duties for a private share issuance, not a financial statement (Annual Report, Interim Report, etc.), not a dividend notice, nor a board change, M&A, or earnings release. It is a regulatory compliance filing that does not fit into any other specific category, making it a general Regulatory Filing (RNS).
2026-05-14 Chinese
关于公司原料药获得FDA注册批准函的公告
Regulatory Filings Classification · 72% confidence The document is a public company announcement regarding FDA approval of an active pharmaceutical ingredient. It has none of the characteristics of financial reports, dividends, share issuances, board changes, or AGM materials. It is a regulatory/compliance update and therefore best fits the fallback category 'Regulatory Filings' (RNS).
2026-05-14 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.